Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy
/in Dendritic Cells, Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2017-04-27 / Sci Rep 2017 04;7(1):1217Temperature measurements in a capacitive system of deep loco-regional hyperthermia
/in Hyperthermia, International Publications /von 2017-04-27 / Electromagn Biol Med 2017;36(3):248-258A short time interval between radiotherapy and hyperthermia reduces in-field recurrence and mortality in women with advanced cervical cancer
/in Cervical Cancer, Hyperthermia, International Publications /von 2017-04-27 / Radiat Oncol 2017 Apr;12(1):75Dendritic cell based vaccination strategy: an evolving paradigm
/in Dendritic Cells, Glioblastoma, International Publications /von 2017-04-22 / J. Neurooncol. 2017 Jun;133(2):223-235Treatment outcomes of concurrent hyperthermia and chemoradiotherapy for pancreatic cancer: Insights into the significance of hyperthermia treatment
/in Hyperthermia, International Publications, Pancreatic Cancer /von 2017-04-21 / Oncol Lett 2017 Jun;13(6):4959-4964Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2017-04-20 / JCI Insight 2017 Apr;2(8)Efficacy of vaccination with tumor-exosome loaded dendritic cells combined with cytotoxic drug treatment in pancreatic cancer
/in Dendritic Cells, Exosome, International Publications, Pancreatic Cancer /von 2017-04-20 / Oncoimmunology 2017;6(6):e1319044Immune Modulation by Vitamin D: Special Emphasis on Its Role in Prevention and Treatment of Cancer
/in International Publications, Micronutrients /von 2017-04-18 / 2017 May;39(5):884-893Combination therapy with dendritic cells and lenalidomide is an effective approach to enhance antitumor immunity in a mouse colon cancer model
/in Colorectal Cancer, Dendritic Cells, International Publications /von 2017-04-18 / Oncotarget 2017 Apr;8(16):27252-27262
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de